Compare HRB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRB | NAMS |
|---|---|---|
| Founded | 1955 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 1994 | N/A |
| Metric | HRB | NAMS |
|---|---|---|
| Price | $40.38 | $32.27 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $41.00 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.8M | 977.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 3.38 | N/A |
| Revenue | ★ $3,159,931,000.00 | N/A |
| Revenue This Year | $4.39 | $17.96 |
| Revenue Next Year | $3.21 | $540.65 |
| P/E Ratio | $12.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.16 | $21.14 |
| 52 Week High | $56.76 | $42.21 |
| Indicator | HRB | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 46.76 |
| Support Level | $29.24 | $29.23 |
| Resistance Level | $44.86 | $37.29 |
| Average True Range (ATR) | 1.15 | 2.05 |
| MACD | 0.15 | -0.44 |
| Stochastic Oscillator | 53.70 | 31.22 |
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.